289 related articles for article (PubMed ID: 16849551)
1. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
3. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Totzke G; Schulze-Osthoff K; Jänicke RU
Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
7. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells.
Nzeako UC; Guicciardi ME; Yoon JH; Bronk SF; Gores GJ
Hepatology; 2002 Mar; 35(3):552-9. PubMed ID: 11870367
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
10. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
Martin S; Phillips DC; Szekely-Szucs K; Elghazi L; Desmots F; Houghton JA
Cancer Res; 2005 Dec; 65(24):11447-58. PubMed ID: 16357153
[TBL] [Abstract][Full Text] [Related]
12. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Cheng AS; Chan HL; Leung WK; Wong N; Johnson PJ; Sung JJ
Int J Oncol; 2003 Jul; 23(1):113-9. PubMed ID: 12792783
[TBL] [Abstract][Full Text] [Related]
13. Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells.
Pan YY; Xu SP; Jia XY; Xu HQ; Zhang Y; Rui LX; Wei W
Exp Oncol; 2007 Mar; 29(1):23-9. PubMed ID: 17431384
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.
Lu G; Liu Y; Ji B; Wei F; Hao C; Wang G
Cancer Invest; 2010 Jul; 28(6):629-34. PubMed ID: 20394499
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.
He Q; Luo X; Jin W; Huang Y; Reddy MV; Reddy EP; Sheikh MS
Oncogene; 2008 Apr; 27(18):2656-60. PubMed ID: 17968315
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
Jendrossek V; Handrick R; Belka C
FASEB J; 2003 Aug; 17(11):1547-9. PubMed ID: 12824303
[TBL] [Abstract][Full Text] [Related]
20. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma.
Shiraki K; Yamanaka T; Inoue H; Kawakita T; Enokimura N; Okano H; Sugimoto K; Murata K; Nakano T
Int J Oncol; 2005 May; 26(5):1273-81. PubMed ID: 15809718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
